A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Elevated plasma sTIM-3 levels in severe Covid-19 patients

J Allergy Clin Immunol.

Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, Jenum S, Jørgensen MJ, Barratt-Due A, Skeie LG, Nordøy I, Aanensen Fraz MS, Quist-Paulsen E E, Pischke SE, Johal SK, Hesstvedt L, Bogen M, Fevang B, Halvorsen B, Müller F, Bekken GK, Mollnes TE, Dudman S, Aukrust P, Dyrhol-Riise AM, Holter JC

doi: 10.1016/j.jaci.2020.09.007.

Further Publications Dermatology

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

N Engl J Med

Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B, BCN-PEP-CoV2 Research Group.

doi: 10.1056/NEJMoa2021801

ImmunotherapyFurther Publications Dermatology

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

JAMA

Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, Stemer A, Mayer SM, Wohl D, Brengle B, Montague BT, Frank I, McCulloh RJ, Fichtenbaum CJ, Lipson B, Gabra N, Ramirez JA, Thai C, Chege W, Gomez Lorenzo MM, Sista N, Farrior J, Clement ME, Brown ER, Custer KL, Van Naarden J, Adams AC, Schade AE, Dabora MC, Knorr J, Price KL, Sabo J, Tuttle JL, Klekotka P, Shen L, Skovronsky DM, BLAZE-2 Investigators.

doi: 10.1001/jama.2021.8828

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Ann Rheum Dis.

Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L, SARI-RAF Study Group., SARI-RAF Study Group members.

doi: 10.1136/annrheumdis-2020-218122.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Arthritis Care Res (Hoboken).

Sirotich E, Dillingham S, Grainger R, Hausmann JS, COVID-19 Global Rheumatology Alliance Steering Committee.

doi: 10.1002/acr.24257.

Allergic Diseases

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Allergy.

Du H, Dong X, Zhang JJ, Cao YY, Akdis M, Huang PQ, Chen HW, Li Y, Liu GH, Akdis CA, Lu XX, Gao YD

doi: 10.1111/all.14452.

Further Publications Dermatology

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

N Engl J Med

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV

doi: 10.1056/NEJMoa2030340

Immune ResponseFurther Publications Immunology

Chemokines and Eicosanoids Fuel the Hyperinflammation Within the Lungs of Patients with Severe COVID-19

J Allergy Clin Immunol

Zaid Y, Doré É, Dubuc I, Archambault AS, Flamand O, Laviolette M, Flamand N, Boilard É, Flamand L

doi: 10.1016/j.jaci.2021.05.032

Further Publications Immunology

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

J Clin Immunol

Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, Brun AL, Cerf C, Chabi ML, Chinet T, Colombier MA, Farfour E, Fourn E, Géri G, Khau D, Marroun I, Ponsoye M, Roux A, Salvator H, Schoindre Y, Si Larbi AG, Tchérakian C, Vasse M, Verrat A, Zuber B, Couderc LJ, Kahn JE, Groh M, Ackermann F, Foch COVID-19 Study Group.

doi: 10.1007/s10875-020-00911-6

Related content

Elevated plasma sTIM-3 levels in severe Covid-19 patients

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Chemokines and Eicosanoids Fuel the Hyperinflammation Within the Lungs of Patients with Severe COVID-19

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis